Key Insights

Highlights

Success Rate

83% trial completion

Published Results

19 trials with published results (25%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

7.9%

6 terminated out of 76 trials

Success Rate

82.9%

-3.6% vs benchmark

Late-Stage Pipeline

8%

6 trials in Phase 3/4

Results Transparency

66%

19 of 29 completed with results

Key Signals

19 with results83% success

Data Visualizations

Phase Distribution

63Total
Not Applicable (8)
Early P 1 (1)
P 1 (20)
P 2 (28)
P 3 (3)
P 4 (3)

Trial Status

Completed29
Recruiting21
Unknown11
Active Not Recruiting8
Terminated6
Withdrawn1

Trial Success Rate

82.9%

Benchmark: 86.5%

Based on 29 completed trials

Clinical Trials (76)

Showing 20 of 20 trials
NCT05602194Phase 3Recruiting

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

NCT01177527Active Not Recruiting

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

NCT06364423Phase 1Recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

NCT06289673Phase 4Recruiting

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

NCT06533748Phase 2Recruiting

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

NCT03178617Not ApplicableActive Not Recruiting

High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma

NCT06514794Phase 2Recruiting

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

NCT07224100Phase 2Recruiting

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

NCT05428176Not ApplicableActive Not Recruiting

A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors

NCT07020533Phase 1Recruiting

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

NCT06207123Phase 1Recruiting

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

NCT02845882Phase 3Active Not RecruitingPrimary

LBL-2016 for Children or Adolescents in China

NCT06918431Phase 2Recruiting

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT01962636Not ApplicableRecruiting

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

NCT04195633Phase 2Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT03810196Not ApplicableRecruiting

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

NCT01574274Phase 2Active Not Recruiting

SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma

NCT03932903Not ApplicableRecruiting

Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

NCT07246213Recruiting

CAYA Cancer Retrospective Cohort Study

NCT02881086Phase 3Completed

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Scroll to load more

Research Network

Activity Timeline